Patent NZ-525779-A (NZ)
Title: Use of substituted imidazo[1,2-A]pyridine-, imidazo [1,2-A]pyrimidine and imidazo[1,2-A]pyrazine-3-YL-amine derivatives for producing nos-inhibiting medicaments
Inventor: SUNDERMANN BERND
IPC: A61K31/519
Filed: 2001-10-10
Abstract: The compound of formula (I) wherein: X is CR4 or N; Y is CR5 or N; and X and Y do not simultaneously represent N, W represents N or NR8; R1 is C1-12-alkyl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted; C3-8-cycloalkyl or CH2-C3-8-cycloalkyl, wherein the cycloalkyl is saturated or unsaturated, and optionally substituted; heterocyclyl, which is saturated or unsaturated, and is optionally substituted; aryl, which is optionally substituted; heteroaryl, which is optionally substituted; C1-8-alkyl-aryl or C1-8-alkyl-heteroaryl, wherein alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted, aryl is optionally substituted, and heteroaryl is optionally substituted, R2 is hydrogen or C(=O)R9; R3 is C1-8-alkyl, wherein alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted; C3-8-cycloalkyl, which is saturated or unsaturated, and optionally substituted; heterocyclyl, which is saturated or unsaturated, and optionally substituted; aryl, which is optionally substituted; heteroaryl, which is optionally substituted; C1-8-alkyl-C3-8-cycloalkyl, C1-8-alkyl-heterocyclyl, C1-8-alkyl-aryl or C1-8-alkyl-heteroaryl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted, the cycloalkyl is saturated or unsaturated and optionally substituted, the heterocyclyl is saturated or unsaturated and optionally substituted, the aryl is optionally substituted; R4, R5, R6 and R7 are hydrogen, or C1-8-alkyl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted; C3-8-cycloalkyl or CH2-C3-8-cycloalkyl, wherein the cycloalkyl is saturated or unsaturated, and optionally substituted; F, Cl, Br, I, CN, NO2, NH2, C(=O)R9, CO2H, CO2R10, OH or OR11; or R4 and R5 or R5 and R6 or R6 and R7 represent a four-membered saturated or unsaturated hydrocarbon bridge having zero, 1, 2 or 3 hetero atoms selected from the group consisting of N, O and S, and the others of R4, R5, R6 and R7 are hydrogen, R8 is C(=O)R9; R9 is C1-8-alkyl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted; C3-8-cycloalkyl or CH2-C3-8-cycloalkyl, wherein the cycloalkyl is saturated or unsaturated, and optionally substituted; heterocyclyl, which is saturated or unsaturated, and optionally substituted; aryl, which is optionally substituted; heteroaryl, which is optionally -substituted; C1-8-alkyl-aryl or C1-8-alkyl-heteroaryl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted, the aryl is optionally substituted, and the heteroaryl is optionally substituted; and R10 and R11 are each independently C1-8-alkyl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally substituted; C3-8-cycloalkyl or CH2-C3-8-cycloalkyl, wherein the cycloalkyl is saturated or unsaturated, and optionally substituted; aryl, which is optionally substituted; C1-8-alkyl-aryl, wherein the alkyl is straight-chained or branched, saturated or unsaturated, and optionally -substituted, and the aryl optionally substituted; is used in the manufacture of a medicament for the treatment of inflammatory pain, migraine, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, cerebral ischaemia, diabetes, meningitis, arteriosclerosis and for healing wounds.